# CIK in Treating Patients With Bladder Cancer

> **NCT02489890** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The First People's Hospital of Changzhou** · enrollment: 1500 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **BIOLOGICAL:** Cytokine-induced Killer Cells

## Key facts

- **NCT ID:** NCT02489890
- **Lead sponsor:** The First People's Hospital of Changzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-02
- **Primary completion:** 2025-07
- **Final completion:** 2030-07
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2016-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489890, "CIK in Treating Patients With Bladder Cancer". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02489890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*